Related Experiment Videos
Targeting Raf-kinase: molecular rationales and translational issues
M Caraglia1, P Tassone, M Marra
1National Cancer Institute Fondazione G. Pascale, Experimental Oncology Department, Experimental Pharmacology Unit, Naples, Italy.
Summary
Targeting Raf-kinase, a key pathway in tumor cell survival, offers promise for cancer therapy. Inhibitors like sorafenib show potential by blocking proliferation and neo-angiogenesis, warranting further clinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Target-based cancer therapies show promise but face limitations in clinical settings.
- Compensatory downstream pathways can hinder the efficacy of traditional anti-cancer strategies.
- Identifying molecular targets is crucial for predicting clinical response.
Purpose of the Study:
- To review the structure, function, and relevance of the Raf-kinase family in tumor cell proliferation and survival.
- To illustrate signal transduction pathways regulated by Raf-kinases.
- To discuss preclinical and clinical results of the Raf-kinase inhibitor sorafenib (BAY 43-9006).
Main Methods:
- Literature review of Raf-kinase family components and signaling pathways.
- Analysis of preclinical and clinical data for sorafenib (BAY 43-9006).
- Discussion of sorafenib's multi-target function and therapeutic potential.
Main Results:
- Raf-kinase family members play a significant role in tumor cell proliferation and survival.
- Sorafenib (BAY 43-9006) has demonstrated preclinical and clinical activity.
- Sorafenib exhibits multi-target functions, inhibiting both cancer proliferation and neo-angiogenesis.
Conclusions:
- Raf-kinase represents an attractive therapeutic target for anti-cancer strategies.
- Sorafenib's dual inhibition of proliferation and neo-angiogenesis offers new therapeutic opportunities.
- Further preclinical and clinical studies are needed to evaluate sorafenib's efficacy in monotherapy and combination treatments.